These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31960533)

  • 21. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal mucosal immunity is unimportant for polio eradication: the failure of oral polio vaccination.
    John TJ; Dharmapalan D; Hirschhorn N
    Infect Dis (Lond); 2024 Aug; 56(8):669-677. PubMed ID: 38889538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria.
    Kalkowska DA; Franka R; Higgins J; Kovacs SD; Forbi JC; Wassilak SGF; Pallansch MA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):289-302. PubMed ID: 32348621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging challenges to realizing global polio eradication and their solutions.
    M A S
    East Mediterr Health J; 2022 Jul; 28(7):515-520. PubMed ID: 35959667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.
    Badizadegan K; Kalkowska DA; Thompson KM
    Med Decis Making; 2023; 43(7-8):850-862. PubMed ID: 37577803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.
    Duintjer Tebbens RJ; Thompson KM
    Expert Rev Vaccines; 2018 Aug; 17(8):739-751. PubMed ID: 30056767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
    Thompson KM; Kalkowska DA; Badizadegan K
    Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An economic analysis of poliovirus risk management policy options for 2013-2052.
    Duintjer Tebbens RJ; Pallansch MA; Cochi SL; Wassilak SG; Thompson KM
    BMC Infect Dis; 2015 Sep; 15():389. PubMed ID: 26404632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Pakistan and Afghanistan.
    Kalkowska DA; Duintjer Tebbens RJ; Pallansch MA; Thompson KM
    Risk Anal; 2019 Feb; 39(2):402-413. PubMed ID: 30296340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2017 Jul; 216(suppl_1):S176-S182. PubMed ID: 28838194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.
    Bandyopadhyay AS; Modlin JF; Wenger J; Gast C
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S35-S41. PubMed ID: 30376081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Facility-Associated Release of Polioviruses into Communities-Risks for the Posteradication Era.
    Bandyopadhyay AS; Singh H; Fournier-Caruana J; Modlin JF; Wenger J; Partridge J; Sutter RW; Zaffran MJ
    Emerg Infect Dis; 2019 Jul; 25(7):1363-1369. PubMed ID: 31082331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. World Health Organization Guidelines for Containment of Poliovirus Following Type-Specific Polio Eradication - Worldwide, 2015.
    Previsani N; Tangermann RH; Tallis G; Jafari HS
    MMWR Morb Mortal Wkly Rep; 2015 Aug; 64(33):913-7. PubMed ID: 26313474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The final stages of the global eradication of poliomyelitis.
    Grassly NC
    Philos Trans R Soc Lond B Biol Sci; 2013 Aug; 368(1623):20120140. PubMed ID: 23798688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
    Minor PD
    Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.
    Patel M; Cochi S
    J Infect Dis; 2017 Jul; 216(suppl_1):S1-S8. PubMed ID: 28838196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.